FDA APPROVED...Gazyva (obinutuzumab) for use i... - CLL Support
FDA APPROVED...Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated CLL.
You need to be a member of this community to see this post.
Read more about...
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Arzerra(R) (Ofatumumab) granted FDA 'Breakthrough Therapy Designation' for Previously Untreated CLL
Genmab A/S and GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA)...
GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia
GAZYVA, a new anti-CD20 monoclonal antibody, is now Therapeutic Goods Administration (TGA)...
Obinutuzumab was approved for treatment naive patients, but in only in combination with chlorambucil.
Friends
Obinutuzumab was approved for treatment naive patients, but in only in combination with...
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the...
acalabrutinib gets Breakthrough Therapy Designation for CLL from FDA
https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-granted-us-breakthrough-thera
Related Posts
- Frontline Venetoclax/Obinutuzumab Approved in Europe for CLL
- Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
B-PLL: Ibrutrinib Monotherapy or Obinutuzumab (aka Gazyva) & Venetoclax Combination as first-line treatment for transformed CLL- News - Acalabrutinib approved for Restricted use in Scotland
